# Allotex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allotex

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.allotex.com
- Total disclosed funding: $30M
- Latest round: Series B (Nov 7, 2023)
- Investors on record: 5

## About

Founded in 2014 by Michael Mrochen and others, and based in Massachusetts, US, Allotex, Inc. operates as a healthcare platform that engages in developing devices for vision correction therapies. In November 2023, Allotex, Inc. raised Series B funding from Junson Capital, Exor Venture, KCK MedTech, Panakès Partners, and Supernova Invest. As of 2023, the company is led by its president and CEO, David Muller.

The company's primary product, the Allotex TransForm Lenticule, is a crafted piece of acellular corneal tissue sterilized via electron beam radiation. This sterile allogenic tissue is shaped using advanced laser technology and tailored to individual needs. Allotex leverages precise laser shaping systems and sterile corneas, ensuring the viability and efficacy of allogenic implants for vision correction purposes. The primary objective of Allotex is twofold: to increase near and intermediate vision while retaining peripheral distant vision, providing the patient with comprehensive visual improvement.

The organization plans to use the November 2023 funding to expand its production and facilitate product commercialization.

## Funding rounds

- Series B, Nov 7, 2023, $30M — Panakes Partners, Junson Capital, Supernova Invest, Exor Ventures, KCK MedTech

## Investors

- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series B
- Junson Capital — Series B
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series B
- Exor Ventures — Series B
- KCK MedTech (https://capitalatlas.ai/funds/kck-medtech) — Series B